SecBot SecBot
SECBOTREPLAY Home › Report › UTHR

UTHR · United Therapeutics CEO Martine Rothblatt and other insiders engaged in…

UNITED THERAPEUTICS Corp · CLUSTER filed Mar 16, 2026 at 16:31 ET

At the news

NEUTRALIMPACT 4/10

CLUSTER filed Mar 16, 2026 at 16:31 ET

United Therapeutics CEO Martine Rothblatt and other insiders engaged in a series of derivative exercises and open-market sales over the past week, with total open-market sales by insiders amounting to approximately $1.28 million. The majority of the activity consists of non-cash transactions (derivative exercises and tax withholdings), including a large tax-related share surrender worth $7.3 million by the CEO. The open-market selling was modest in dollar terms relative to the company's $23.1B market cap.

  • CEO Martine Rothblatt sold 1,657 shares in open-market transactions totaling ~$1.07 million at prices between $522.88 and $534.99.
  • EVP Paul Mahon sold 753 shares in open market for ~$397K.
  • Director Malcolm Jan sold 45 shares for ~$24K; Director Judy Olian sold 200 shares for ~$107K.
  • CEO and EVP exercised derivatives totaling 9,500 and 8,300 shares respectively on multiple dates, with exercise prices of $146.03 and $0.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access